|    editor@medjpps.com

www.medjpps.com

Received date : 12-05-2022 Revised date : 10-06-2022 Accepted date : 14-06-2022 Published date : 30-06-2022

Mediterr J Pharm Pharm Sci 2 (2): 53 - 65, 2022

DOI: https://doi.org/10.5281/zenodo.6780500

Original Research


Incidence of agranulocytosis adverse effect of antipsychotic drugs in patients with schizophrenia

Suhera M. Aburawi, Mabruk E. Erhuma, Mohammed A. Mussa



Abstract :

Schizophrenia is treated with antipsychotic drugs and is a chronic neuropsychiatric disorders. The influence of antipsychotics on the cytokine systems may be responsible for their clinical efficacy in schizophrenia. Granulocytopenia and agranulocytosis are severe side effects of antipsychotic therapy. The objective of this study was to estimate incidence of drug-associated agranulocytosis in newly diagnosed schizophrenic patients in and to evaluate the risk factors and outcomes. Seven participants groups were designed. Healthy persons as control. Schizophrenic patients before treatment. Schizophrenic patients after one-month of treatment. Schizophrenic patients after two - month of treatment. Schizophrenic patients after three - month of treatment. Schizophrenic patients after chronic treatments. Schizophrenic patients one month after chronic treatment. This study included screening for the expression and function of circulating leukocyte granulocyte-macrophage colony-stimulating factor receptor, screening of patient's biochemistry and haematology picture. Granulocyte-macrophage colony-stimulating factor expression was decreased after antipsychotic treatment for one month and continued to decrease after two months' treatment. Granulocyte-macrophage colony-stimulating factor expression starts to increase after the two-month treatment and continues increasing to controls or newly diagnosed schizophrenics or after chronic treatment. Complete blood counts were not changed compared. Liver function showed a transient increase in serum alkaline phosphatase after one and two month of treatment. All other parameters were not changed. Kidney function showed that urea and creatinine levels were within the normal range during the different treatments. Concerning lipid profile, low density lipoproteins levels were increased after one month, two months of treatment and after chronic administration of the antipsychotic drugs. It is concluded that antipsychotic treatment produces a decrease in granulocyte-macrophage colony-stimulating factor expression; the decrease reach the maximum effect after two months, then starts to increase back to normal levels. A transient increase in serum alkaline phosphatase in the first two months' treatment. Urea and creatinine levels and lipid profile were within normal range, except low density lipoproteins levels were increased during the two months treatment and after chronic administration of the antipsychotic drugs.

Share :